The compound of the formula wherein the * indicates an asymmetric
carbon, is specific to alpha.sub.2B adrenergic receptors in preference
over alpha.sub.2A and alpha.sub.2C adrenergic receptors, and as such has
no or only minimal cardivascular and/or sedatory activity. The compound
is useful as medicament in mammals, including humans, for treatment of
diseases and or alleviations of conditions which are responsive to
treatment by agonists of alpha.sub.2B adrenergic receptors.